We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $529M
1-Year Est. Return 337.4%
This Fund
S&P 500
This Quarter Est. Return
-10.43%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.24%
AUM
$957M
AUM Growth
-$191M
Cap. Flow
-$17M
Cap. Flow %
-1.78%
Top 10 Hldgs %
64.82%
Holding
49
New
12
Increased
12
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$59.6M
2
ABMD
Abiomed Inc
ABMD
+$35.9M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$32.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.7M
5
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$29.3M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$69.6M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$50.4M
3
DERM
Dermira, Inc.
DERM
+$39.7M
4
TGTX icon
TG Therapeutics
TGTX
+$36.4M
5
XLRN
Acceleron Pharma
XLRN
+$36.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.53%
2 Miscellaneous 7.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
26
Cytokinetics
CYTK
$9.64B
$7.83M 0.82%
664,097
+504,024
+315% +$6.43M
VRAY
27
DELISTED
ViewRay, Inc.
VRAY
$6.93M 0.72%
2,773,811
+1,058,658
+62% +$3M
LQDA icon
28
Liquidia Corp
LQDA
$5.88B
$6.02M 0.63%
1,277,955
– –
AXSM icon
29
Axsome Therapeutics
AXSM
$10.7B
$5.89M 0.62%
100,100
+99,846
+39,309% +$8.14M
ARVN icon
30
Arvinas
ARVN
$540M
$4.77M 0.5%
118,330
-431,670
-78% -$20.2M
YARW
31
Yarrow Bioscience
YARW
$68.1M
$4.43M 0.46%
459
– –
ARVN icon
32
CALL
Arvinas
ARVN
$540M
$4.17M 0.44%
+103,500
New +$4.84M
SGMO
33
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.04M 0.42%
+633,505
New +$4.7M
KURA icon
34
Kura Oncology
KURA
$1.01B
$1.79M 0.19%
179,700
-674,077
-79% -$7.72M
CTMX icon
35
CytomX Therapeutics
CTMX
$586M
$1.07M 0.11%
+139,718
New +$974K
NGNE icon
36
Neurogene
NGNE
$674M
$459K 0.05%
+2,017
New +$415K
ATRA icon
37
Atara Biotherapeutics
ATRA
$94.8M
– –
-2,800
Closed -$1.15M
AUPH icon
38
CALL
Aurinia Pharmaceuticals
AUPH
$2.15B
– –
-1,000,000
Closed -$20.3M
AXSM icon
39
CALL
Axsome Therapeutics
AXSM
$10.7B
– –
-727,200
Closed -$75.2M
BBIO icon
40
BridgeBio Pharma
BBIO
$13.4B
– –
-78,400
Closed -$2.75M
DXCM icon
41
DexCom
DXCM
$32.6B
– –
-104,400
Closed -$5.71M
GNFT
42
DELISTED
Genfit
GNFT
– –
-207,766
Closed -$4.13M
INSM icon
43
Insmed
INSM
$26.2B
– –
-97,359
Closed -$2.33M
IONS icon
44
Ionis Pharmaceuticals
IONS
$7.85B
– –
-65,000
Closed -$3.93M
OPTN
45
DELISTED
OptiNose
OPTN
– –
-78,789
Closed -$10.9M
TNDM icon
46
Tandem Diabetes Care
TNDM
$1.13B
– –
-250,000
Closed -$14.9M
DERM
47
DELISTED
Dermira, Inc.
DERM
– –
-2,621,333
Closed -$39.7M
ZGNX
48
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-250,000
Closed -$13M
ZGNX
49
DELISTED
Zogenix, Inc.
ZGNX
– –
-420,000
Closed -$21.9M
1
2

Similar funds

KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
FFIC
First Fiduciary Investment Counsel Cleveland, Ohio $529M AUM 15.02% 1-Year Est. Return
TA
Teramo Advisors Naples, Florida $529M AUM 20.59% 1-Year Est. Return
JDLA
J. Derek Lewis & Associates Newport Beach, California $529M AUM
CCG
Clearlake Capital Group Santa Monica, California $529M AUM 50.26% 1-Year Est. Return
DAS
DMKC Advisory Services Des Moines, Iowa $530M AUM 22.27% 1-Year Est. Return
VAMG
Voisard Asset Management Group Grand Rapids, Michigan $529M AUM 21.43% 1-Year Est. Return
CWM
Compass Wealth Management Guilford, Connecticut $528M AUM 40.26% 1-Year Est. Return

Great Point Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Great Point Partners held 49 positions worth $957M, down 17% from $1.15B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Great Point Partners's Q1 2020 filing shows 12 new, 12 increased, 7 reduced and 13 closed positions. Its largest new stake was Abiomed Inc: 216,144 shares worth $31.4M. The largest sale was Iovance Biotherapeutics, an estimated $69.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

  • Great Point Partners's largest Q1 2020 buy was Abiomed Inc: 216,144 shares worth $31.4M.
  • Great Point Partners added most to Sage Therapeutics in Q1 2020, an estimated $59.6M increase.
  • Great Point Partners's biggest Q1 2020 reduction was Iovance Biotherapeutics, cutting an estimated $69.6M.
  • Great Point Partners fully exited Dermira, Inc. in Q1 2020, selling an estimated $39.7M.
  • Great Point Partners's ten largest holdings make up 65% of its $957M portfolio in Q1 2020.
  • Great Point Partners opened 12 new positions and closed 13 in Q1 2020.
  • Great Point Partners's portfolio value fell 17% quarter-over-quarter to $957M.

Based on Great Point Partners's 13F filing for Q1 2020, filed 15 May 2020.